Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cost of Drug Development Reduced Thanks to New Technology

Published: Friday, January 18, 2013
Last Updated: Friday, January 18, 2013
Bookmark and Share
De Montfort University (DMU) has come together with Ithaka Life Sciences Ltd to market new technology designed to speed up and reduce the cost of the development of new drugs and medicines.

A leading expert at DMU, Professor Bob Chaudhuri, has invented the technology which will provide useful new products and services, based on a set of proteins, named cytochrome P450s (CYPs).

CYPs are found in the human liver and are mostly responsible for the metabolism of drugs in people. These proteins are commercially available for use by companies involved in the discovery of new drugs, but are inconvenient to use as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.

This new technology allows for CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain. This will reduce the cost and make their use in testing new drugs much quicker and easier.

Together, DMU and Ithaka have established a new company which will be called CYP Design Ltd (CDL).

Professor Chaudhuri said: “The development of new drugs can be very time-consuming and costly. It can take up to 14 years from the initial idea and cost hundreds of millions of pounds. Thousands of potential new drugs are tested initially for every one successfully brought to market.

“Early drug discovery work has to identify new chemical compounds which are potentially useful without being toxic to humans. Current testing methodologies do not address the problem as these model systems often react differently than humans to new chemicals.

“My group’s development is designed to provide the proteins that are needed for this work in a cost effective and convenient format.

DMU has licensed this new technology to CDL which is now seeking to bring the new products to market. Ithaka has worked closely with Professor Chaudhuri to set up CDL and is leading the implementation of the business strategy through Dr Bill Primrose as CEO and Dr Paul Rodgers as Chairman.

Dr Bill Primrose said: “We’re delighted to be working with DMU and believe that the technology that Professor Chaudhuri has been developing can have a significant impact on the timescales and costs involved in the early stages of drug discovery.

“CYPs are currently transported on dry ice, at around minus 80 degrees Celsius, and are stored as cold as possible in the customer’s laboratory until they are needed.

“His new technology eliminates the need for a cold chain making it easier to manufacture and ship the proteins, and making them much more convenient for the customer to use.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!